Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
Mehiläinen Airport Health Center, Vantaa, Finland.
Alpo
A
Vuorio
Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia.
Gerald F
GF
Watts
Wihuri Research Institute, Helsinki, Finland.
Petri T
PT
Kovanen
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL; D057210:Delayed Diagnosis; D006801:Humans; D006937:Hypercholesterolemia; D006938:Hyperlipoproteinemia Type II / Q000175:diagnosis* / Q000188:drug therapy*; D000091362:PCSK9 Inhibitors; D043484:Proprotein Convertases; D000071449:Proprotein Convertase 9
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; D043484:Proprotein Convertases; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9